Our purpose was to assess the relationship between the disease severity of Amyotrophic Lateral Sclerosis (ALS) and the main parameters of Fiberoptic Endoscopic Evaluation of Swallowing (FEES), indirectly hypothesizing for FEES a role as clinical indicator of the progression of ALS. We studied 220 patients (101 women, 119 men) with ALS; of these, 148 had spinal and 72 bulbar onset. They were analyzed according to the Amyotrophic Lateral Sclerosis Functioning Rating Scale (ALSFRS) and the b-ALSFRS subscale (bulbar scale). All subjects underwent FEES. Postswallowing residue was classified into four classes (0-3); premature spillage and aspiration were considered either present or absent. An in-depth statistical analysis revealed a highly significant relationship between the FEES parameters studied and the severity of the disease assessed through ALSFRS and b-ALSFRS (p < 0.0001), no matter what bolus texture was used. Moreover, statistical analysis showed a highly significant association between the classes of severity in bulbar forms and all the FEES parameters, no matter what type of bolus was administered (p <0.0001), whereas a significant correlation in spinal forms only for post-swallowing residue with solid (p= 0.025) and semisolid (p= 0.034) boluses. FEES is a good indicator of the severity of dysphagia and of its progression in patients with ALS, as well as of the clinical progression of the disease.Fiberoptic Endoscopic Evaluation of Swallowing (FEES) is an excellent method in the study of swallowing disorders: it allows to directly view the pharyngeal phase of swallowing, permitting precise assessment of any premature spillage, post-swallowing residue in the hypo-pharyngeal region, as well as penetration and/or aspiration incidents in the lower respiratory tract. It is easy to perform, well tolerated, not requiring exposure to radiation, suitable for bedside examination, inexpensive, and with rare side-effects 1 . It is necessary to remember that potential complications and adverse effects of FEES are very few. In one of our previous studies, we found significant complications such as posterior epistaxis in one patient (0.04%) and laryngospasm only in two patients (0.07%) out of 2,820 patients 1 . Moreover, its repeatability makes FEES especially suitable for the follow-up of dysphagic patients, in particular for patients suffering from Amyotrophic Lateral Sclerosis (ALS) [2][3][4] . ALS is a neurodegenerative disorder characterized by upper and lower motor neuron degeneration. Starting insidiously in adulthood, it leads to death within 1-5 year 5 . The body region of symptoms onset (spinal onset or bulbar onset), the predominant upper or lower motor neuron involvement and the rate of disease progression bring the phenotypic variability.ALS is very frequently complicated with dysphagia, that may be the presenting symptom in 30% of the cases and nevertheless occurs in